Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02066181 · ClinicalTrials.gov registry record · Phase 3
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 87
- Enrollment target
NCT02066181: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT02066181 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 87 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02066181, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 87 participants
- Enrollment target
Study Summary
This randomized phase III trial compares the effects, good and/or bad, of sorafenib tosylate in treating patients with desmoid tumors or aggressive fibromatosis. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. \[Funding Source - FDA OOPD\]
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- OTHER Placebo Administration
- DRUG Sorafenib Tosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2014-03-21 |
| Est. Completion | 2022-12-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02066181
The ClinicalTrials.gov registry entry for NCT02066181 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02066181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02066181 about?
NCT02066181 is a clinical study titled "Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis". This randomized phase III trial compares the effects, good and/or bad, of sorafenib tosylate in treating patients with desmoid tumors or aggressive fibromatosis. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. \[Funding Source - FDA OOPD...
What is the current status of trial NCT02066181?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 87 participants. The study started on 2014-03-21. Estimated completion is 2022-12-01.
What interventions are being tested in trial NCT02066181?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Placebo Administration (OTHER), Sorafenib Tosylate (DRUG).
Who is sponsoring clinical trial NCT02066181?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.